# Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

> **NCT03786094** · PHASE3 · TERMINATED · sponsor: **Spexis AG** · enrollment: 432 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Recurrent Breast Cancer

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Balixafortide

## Key facts

- **NCT ID:** NCT03786094
- **Lead sponsor:** Spexis AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-30
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-10-19
- **Target enrollment:** 432 (ACTUAL)
- **Why stopped:** The study was halted early due to failure to meet the primary endpoint.
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786094, "Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03786094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*